- Datum04.08.2025
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Altan Cantürk
Moderator
Pharma Mar S.A. Aktie
Verkaufen
Kaufen
Pharma Mar S.A. Chart
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Pharma Mar S.A. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (L&S)
-0,63 %
Intraday
-4,11 %
1 Woche
-1,00 %
1 Monat
4,00 %
Seit Jahresbeginn
108,57 %
1 Jahr
37,05 %
3 Jahre
-10,94 %
5 Jahre
Passender Service zu Pharma Mar S.A.
Webinar zu Pharma Mar S.A.
Kursinformationen (L&S)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)34,900-105,700
- Jahrestief / Hoch (€)68,000-105,700
- Schlusskurs (Vortag)
- Eröffnungskurs
Wichtigste Eigenschaften
Dividenden von Pharma Mar S.A.
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| - | 2027 (e) | ||
| - | 2026 (e) | ||
| - | 2025 (e) | ||
| - | 2024 (e) | ||
| - | 2023 (e) | ||
| 07.06.2023 | 2022 | 0,65 € | 1,76 % |
| 13.07.2022 | 2021 | 0,65 € | 0,96 % |
| 28.04.2021 | 2020 | 0,60 € | 0,65 % |
Termine von Pharma Mar S.A.
- Nov11Pharma Mar S.A.Q3 2025 Earnings Release
- Mär2Pharma Mar S.A.Q4 2025 Earnings Release
Beschreibung
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
